27 September 2019 Analysis
Although CV disease is the main cause of death globally, it is a particularly significant issue in developing countries where there are more challenges to accessing medication. One solution to...
17 September 2019 Comment
There are at least 215 possible cases across 25 states where the development of severe lung disease has been linked to vaping.
13 September 2019 News
A research team from Penn Medicine at the University of Pennsylvania has been studying CAR T-cell therapy, which is used to fight cancer, in the treatment of heart disease.
6 September 2019 Comment
The ESC’s updated guidelines are an important step forward in addressing CV risk, which has historically remained an unresolved issue in patients living with diabetes.
4 September 2019 Analysis
At the 2019 ESC congress in Paris, AstraZeneca presented full results from the Phase III DAPA-HF trial studying type 2 diabetes drug Farxiga in HFrEF. The drug showed great promise...
2 September 2019 News
Novartis has announced that its heart failure with reduced ejection fraction (HFrEF) drug Entresto (sacubitril/valsartan) has shown further efficacy in two Phase IV trials, PROVE-HF and EVALUATE-HF.
22 August 2019 Comment
GlobalData believes a decision for an AdCom to be held does not translate negatively to the drug’s chances for a successful FDA label expansion.
20 August 2019 News
AstraZeneca has announced that Farxiga (dapagliflozin) met its primary endpoint in heart failure-focused Phase III DAPA-HF trial of patients with reduced ejection fraction (HFrEF).
19 August 2019 News
Researchers from Virginia Tech University (VT) have developed a variant of the compound alphaCT1, which can improve heart attack recovery if administered during, or soon after, a heart attack.